In the ECHELON-2 trial, the BV + CHP regimen demonstrated a 53% improvement in progression-free survival compared to CHOP in CD30-positive peripheral T-cell lymphomas [9]. The gene discussed is TNFRSF8; the disease is peripheral T-cell lymphoma, not otherwise specified.